Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.55 |
| ▸ | HTR3B | O95264 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.55 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926317 | 0.89 | MEN1 (0.65) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL9248196 | 0.89 | MEN1 (0.65) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL1786140 | 0.88 | MEN1 (0.69) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL4453290 | 0.88 | MEN1 (0.69) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL31139240 | 0.87 | MEN1 (0.63) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL60478 | 0.87 | MEN1 (0.63) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL14720174 | 0.87 | MEN1 (0.63) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL11592049 | 0.87 | MEN1 (0.63) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL27404414 | 0.86 | CHRNA7 (0.55) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| Ammonia Solution, Strong SCHEMBL597060 | 0.85 | MEN1 (0.61) | MEN1KMT2ACHRNA7HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817032-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | claimed |
| US-20060287303-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-12-21 | — | — | US | claimed |
| WO-2006058294-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | claimed |
| US-7880007-B2 | such as 1-bicyclo[2.2.1]hept-2-yl-4-(4-methoxy-2-methyl-phenyl)-piperidine, used for the treatment of chronic obstructive pulmonary disease, asthma, urinary incontinence, vision defects and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | disclosed |
| CN-100528874-C | Pyrrolo [2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS CORP (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-1817032-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060287303-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-12-21 | — | — | US | disclosed |
| CN-1263757-C | Specific for adenosine A1,A2AAnd A3Receptor compounds and uses thereof | OSI PHARMACENTICALS INC (US) | 2006-07-12 | — | — | CN | disclosed |
| WO-2006058294-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
| EP-1347980-A4 | COMPOUNDS SPECIFIC TO ADENOSINE-A1,-A2A, AND- A3-RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2005-02-09 | — | — | EP | disclosed |
| CN-1489590-A | Specific for adenosine A1,A2AAnd A3Receptor compounds and uses thereof | OSI��ҩ��˾ | 2004-04-14 | — | — | CN | disclosed |
| CN-1109749-A | Methods for inhibiting uterine fibrosis | LILLY CO ELI (US) | 1995-10-11 | — | — | CN | disclosed |
| US-5441964-A | Especially post-memopausal women | ELI LILLY AND COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| CN-1105853-A | Methods for inhibiting bone loss | LILLY CO ELI (US) | 1995-08-02 | — | — | CN | disclosed |
| CN-1105362-A | Methods for lowering serum cholesterol | LILLY CO ELI (US) | 1995-07-19 | — | — | CN | disclosed |
| EP-0657162-A1 | Methods for lowering serum cholesterol | ELI LILLY AND COMPANY (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0651998-A1 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0650724-A1 | Methods for inhibiting uterine fibrosis | ELI LILLY AND COMPANY (US) | 1995-05-03 | — | — | EP | disclosed |
| EP-0641791-A1 | NOVEL BENZOTHIOPHENE DERIVATIVE | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| US-4419263-A | Liquid crystalline cyclohexylcarbonitrile derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287303-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | MEN1 2672/4885KMT2A 2362/4885CHRNA7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.